Moderna, Inc. vs Synchrony Financial — how do they compare? Moderna, Inc. trades at $59.72 (market cap $23.60B), while Synchrony Financial trades at $71.7 (market cap $24.69B). The key difference: Moderna, Inc. and Synchrony Financial are close in size by market cap, and Synchrony Financial pays a 1.63% dividend while Moderna, Inc. pays none. Which is the better fit depends on your goals.
| MRNA | SYF | |
|---|---|---|
Market Cap | $23.60B | $24.69B |
Sector | Health | Financials |
52-Week High | $81.80 | $88.47 |
52-Week Low | $22.36 | $63.78 |
Enterprise Value | $19.70B | — |
Dividend Yield | — | 1.63% |
Trailing returns across standard periods
Latest headlines on both assets
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →Synchrony Financial is a premier consumer financial services company and the largest provider of private-label credit cards in the United States. Spun off from GE Capital in 2014, it operates through a unique B2B2C model, embedding its financing products within the ecosystems of major partners like Amazon, Lowe’s, and PayPal. Synchrony leverages deep data analytics and a diverse multi-platform strategy—spanning retail, health, and auto—to drive customer loyalty and provide specialized credit solutions at the point of sale.
Read more on SYF →